MyMedR

Displaying all 3 publications

Abstract:

Sort:

Hotspots of mite new species discovery: Trombidiformes (2013-2015)

Liu JF, Zhang ZQ

Zootaxa, 2016 Dec 14;4208(1):zootaxa.4208.1.1.
PMID: 27988536 DOI: 10.11646/zootaxa.4208.1.1

This paper reveals the hotspots of new mite discovery through of a survey of type localities of new Trombidiformes species described in two journals (Systematic & Applied Acarology and Zootaxa) during the last three years (2013-2015). Taxonomically, the 491 new species of the Trombidiformes are highly unevenly distributed among 55 families with top 10 families accounting for over 66% of the total. The Eriophyidae is the top-ranked family. Geographically, these 491 new species are from 55 countries around the world and their distribution among the countries is highly uneven. The majority of these new species (69%) are from the top 10 countries and six of the top ten countries are also megadiversity countries. The top three countries are all from Asia (Iran, China and Malaysia) and they together accounted for over one third of all new species of the Trombidiformes described in the two journals during 2013-2015.
Diagnosis, assessment, and management of surgical complications following esophagectomy

Grimminger PP, Goense L, Gockel I, Bergeat D, Bertheuil N, Chandramohan SM, et al.

Ann N Y Acad Sci, 2018 12;1434(1):254-273.
PMID: 29984413 DOI: 10.1111/nyas.13920

Despite improvements in operative strategies for esophageal resection, anastomotic leaks, fistula, postoperative pulmonary complications, and chylothorax can occur. Our review seeks to identify potential risk factors, modalities for early diagnosis, and novel interventions that may ameliorate the potential adverse effects of these surgical complications following esophagectomy.
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease

Zhang H, Targher G, Byrne CD, Kim SU, Wong VW, Valenti L, et al.

Hepatol Int, 2024 Aug;18(4):1178-1201.
PMID: 38878111 DOI: 10.1007/s12072-024-10702-5

BACKGROUND: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11.
METHODS: Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members.
RESULTS: A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%).
CONCLUSIONS: This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision.

Filters

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links